Navigation Links
Gene Can Dampen Chemo Drug Effectiveness
Date:6/10/2009

Alternatives to current breast cancer therapy needed for some patients, study says

WEDNESDAY, June 10 (HealthDay News) -- Women with a certain type of gene may show marked resistance to an important chemotherapy drug used to treat breast cancer, new research suggests.

Scientists at the U.S. National Cancer Institute (NCI) suspect that the variation in the SOD2 gene affects how a patient responds to cyclophosphamide, an agent used against breast tumors, blood cancers and other malignancies. The research is the first to show a mechanism and a biomarker for cyclophosphamide resistance.

Although this is not good news for some patients, the findings have a silver lining: New tests may soon be developed to help doctors screen for genetic markers and create "tailored" therapies, according to an NCI news release.

"In the future, such tests may be used to guide the treatment of patients with the SOD2 variation, ensuring that they receive a therapy that is more effective than cyclophosphamide-based therapy," senior study author Stefan Ambs, of the NCI's Center for Cancer Research, said in the news release.

The study, published online June 9 in Clinical Cancer Research, looked at 588 breast cancer patients in Norway and the United States. Those who had the variation experienced poorer survival on the drug, the researchers found. Scientists believe that the SOD2 variant interferes with the structure and function of an important cellular protein.

More information

The American Cancer Society offers more information on breast cancer.



-- Peter West



SOURCE: U.S. National Cancer Institute, news release, June 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Fallout From Failed AIDS Vaccine Could Dampen Research
2. Drinking Dampens Ability to Feel Fear
3. Autoimmune Disease Treatment May Not Dampen Immune System
4. Economy Doesnt Dampen Colorados Giving Spirit According to Statewide Giving and Volunteering Study
5. Experimental Drug May Dampen Severe Asthma
6. Obesity May Dampen Response to Asthma Meds
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. To evade chemotherapy, some cancer cells mimic stem cells
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Can Dampen Chemo Drug Effectiveness 
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: